Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush

Common dermatological side-effects associated with erlotinib, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), include pruritus and skin rash, which are mediated by substance P, leading to the occasional discontinuation of cancer treatment. Aprepitant is an antagonist of neur...

Descripción completa

Detalles Bibliográficos
Autores principales: Seki, Nobuhiko, Ochiai, Ryosuke, Haruyama, Terunobu, Ishihara, Masashi, Natsume, Maika, Fukasawa, Yoko, Sakamoto, Takahiko, Tanzawa, Shigeru, Usui, Ryo, Honda, Takeshi, Ota, Shuji, Ichikawa, Yasuko, Watanabe, Kiyotaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381921/
https://www.ncbi.nlm.nih.gov/pubmed/30792647
http://dx.doi.org/10.1159/000493256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381921/
https://www.ncbi.nlm.nih.gov/pubmed/30792647
http://dx.doi.org/10.1159/000493256

Ejemplares similares